Cardiometabolic Risk Overview

Principles

Definition

Cardiometabolic risk is an academic concept and research area investigating the clustering of interrelated metabolic and physiological abnormalities, including obesity, insulin resistance, dyslipidemia, and hypertension, which collectively significantly increase an individual's likelihood of developing cardiovascular disease and type 2 diabetes.

Ontological type

Risk Factors

Biomarkers

Prevention Strategies

Key developments

Key Figures

Multivariate Risk Integration era

William B. Kannel [1] was a leading figure in this era, with affiliations at Harvard University [3] and the University of California, San Francisco [4]. Kannel [1] and his Diabetes and Cardiovascular Disease [7] paper highlighted the linkage between diabetes and cardiovascular risk, a foundational step toward multivariate risk profiling in clinical practice and public health. Steven N. Blair [2] was a prominent contributor, with affiliations at Stanford University [5] and The University of Texas Southwestern Medical Center [6] during this era. Blair [2] and his 1989 paper Physical Fitness and All-Cause Mortality [8] provided empirical evidence that fitness levels predict mortality, underscoring the role of functional status in multivariate risk assessment for cardiometabolic outcomes.

Inflammation–Metabolic Nexus era

Russell P. Tracy [1] is associated with Harvard University [3] and the University of California, San Francisco [4] during this era. Tracy [1]'s contributions in this era include elucidating markers of inflammation as cardiovascular risk indicators, as highlighted by the paper Markers of Inflammation and Cardiovascular Disease [6], and these insights reframed risk stratification around inflammatory processes. Nader Rifai [2] has affiliations with Harvard University [3] and Stanford University [5] during this era. Rifai [2]'s key contributions in this era include advancing multi-marker inflammatory profiling and validating biomarkers for cardiovascular risk, as exemplified by the paper Markers of Inflammation and Cardiovascular Disease [6], which helped operationalize inflammation as a mediator of vascular injury in metabolic risk.

Omics-Guided Precision Risk era

Salim S. Virani [1], affiliated with Harvard University [3] and the University of California, San Francisco [4], epitomizes the Omics-Guided Precision Risk era. His key contribution in this era is co-authoring Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement [6], which clarified Lp(a) as a cardiometabolic risk biomarker and supported precision risk stratification. Gerald F. Watts [2], linked to Harvard University [3] and the University of Washington [5], contributed to the Lipoprotein(a) consensus statement [6], reinforcing cross-institution collaboration in omics-guided risk frameworks. This Lipoprotein(a) consensus statement [6] illustrates how multi-institution, omics-guided guidance can translate risk signals into clinical guidance and targeted testing within precision cardiometabolic risk.